Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$3.09 USD

3.09
352,879

-0.11 (-3.44%)

Updated Jun 18, 2024 04:00 PM ET

After-Market: $3.08 -0.01 (-0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PBYI vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

PBYI vs. TECH: Which Stock Is the Better Value Option?

SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data

by Zacks Equity Research

SpringWorks (SWTX) posts encouraging data from phase IIb study on its MEK inhibitor, mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas. Stock falls.

Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC

by Zacks Equity Research

The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.

Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates

by Zacks Equity Research

Puma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance.

Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales

by Zacks Equity Research

Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same.

Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss

by Zacks Equity Research

Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.

Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.

Puma Biotech (PBYI) Tops Q3 Earnings Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 13.33% and 3.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

PBYI or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PBYI vs. TECH: Which Stock Is the Better Value Option?

Puma Biotech (PBYI) Loses -18.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Puma Biotech (PBYI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

PBYI vs. AMGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

PBYI vs. AMGN: Which Stock Is the Better Value Option?

Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC

by Zacks Equity Research

Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.

Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform

by Zacks Equity Research

Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 42.86% and 6.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PBYI vs. GMAB: Which Stock Is the Better Value Option?

Ekta Bagri headshot

5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.

Bluebird (BLUE) Down 26% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PBYI or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PBYI vs. TECH: Which Stock Is the Better Value Option?

Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now

by Zacks Equity Research

Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.

PBYI vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

PBYI vs. TECH: Which Stock Is the Better Value Option?

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y

by Zacks Equity Research

Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.

Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 550% and 6.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of -35.09% and 7.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top

by Zacks Equity Research

Puma Biotechnology's (PBYI) Q4 2022 loss is wider than estimates, Revenues beat the same.

CERT vs. PBYI: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CERT vs. PBYI: Which Stock Is the Better Value Option?